Burrill & Company closes second Burrill Capital Fund IV
Burrill & Company, a global life sciences financial services firm, announced a second close of its Burrill Capital Fund IV, bringing the aggregate capital commitments to $505 million.
The fund will invest globally in the life sciences, including early- to late-stage investments in therapeutics, diagnostics, medical devices, healthcare delivery, wellness, and digital health.
"We are pleased that our new fund generated strong interest among investors," said G. Steven Burrill, CEO of Burrill & Company. "This is a time of great opportunities globally for investors in the life sciences, not just in traditional sectors, but emerging areas brought about by the convergence of healthcare and information technology."